
Ajanta Pharma Posts Its Steepest Single-Day Fall in Six Months With No Disclosed Trigger
Ajanta Pharma Rs 3,512, down 2.82% (1 Oct, 10:12 AM). Steepest single-day fall in six months, no confirmed trigger disclosed. RSI 49.2. P/E 39.83 vs industry 38.34.
Updated: 1 Oct 2026 • 10:21 am
Posted by:

Quick Answer
The Ajanta Pharma share price fell 2.82 percent to Rs 3,512 at 10:12 AM on 1 October 2026, its steepest single-day decline in six months. No specific company disclosure explaining the fall was found in the filings reviewed, so this article does not assign a cause beyond the price move itself. The stock's RSI of 49.2 is neutral despite today's sharp fall, since the broader multi-week trend had been comparatively stable before this move. Ajanta Pharma trades at a P/E of 39.83, close to the pharmaceutical industry average of 38.34, so the stock is neither at a significant premium nor discount following today's decline.
Ajanta Pharma Limited shares fell sharply on Wednesday, with the stock down as much as 2.67 percent during the session and extending to a 2.82 percent decline by Thursday morning, marking its largest single-day fall in six months. No specific corporate announcement accompanying the decline was found in the disclosures reviewed.
Click Here – Get Free Investment Predictions
The specialty pharmaceutical formulation company has otherwise had a relatively stable multi-week run, making today's move a notable outlier. This article sets out the numbers, the stock's valuation, and the risks investors should weigh given the absence of a confirmed trigger.
What Is Known About Today's Ajanta Pharma Fall
| Item | Detail |
|---|---|
| Fall | 2.82% to Rs 3,512 (as of 10:12 AM) |
| Context | Steepest single-day fall in six months |
| Confirmed company disclosure | None found in filings reviewed |
| Volume | Below typical five-day average turnover in the screenshot reviewed |
Sharp single-day moves without an accompanying company announcement can reflect broader sector rotation, profit-booking after a prior run-up, or reaction to sector-wide news such as US FDA inspection trends across Indian pharma exporters, none of which is confirmed specifically for Ajanta Pharma in the information available. Investors should treat the absence of a disclosed trigger as a reason for caution rather than assume a benign explanation.
Also read – Stocks to Watch Today: Alicon Castalloy Jumps 20%, Ircon and Rites Surge on Heavy Volume
Ajanta Pharma Share Price Today: Numbers and Technical Levels
| Metric | Value (1 Oct, 10:12 AM) |
|---|---|
| Ajanta Pharma share price | Rs 3,512.00 (down 2.82%) |
| Previous close | Rs 3,620.80 |
| Day range | Rs 3,489.60 to Rs 3,602.40 |
| 52-week high / low | Rs 3,796.00 / Rs 2,329.90 |
| RSI (14-day) | 49.2 |
| SuperTrend | Bearish, resistance at Rs 3,740.42 |
| 20-day average | Rs 3,534.12 |
| Market cap | Rs 45,203 crore |
| P/E vs industry P/E | 39.83 vs 38.34 |
| Return on equity | 23.33% |
The Ajanta Pharma share price is 7.5 percent below its 52-week high of Rs 3,796 and has fallen just below its 20-day average of Rs 3,534.12. The RSI of 49.2 remains neutral, suggesting today's drop has not yet pushed the stock into oversold territory on a 14-day basis.
Compare Pharma Stocks and Live Levels on the Univest Screener
Valuation Behind the Ajanta Pharma Share Price
Ajanta Pharma trades at a P/E of 39.83, close to the pharmaceutical industry average of 38.34, so the stock is roughly in line with sector peers after today's fall. Return on equity of 23.33 percent and debt to equity of just 0.06 remain strong, underpinning a business with limited leverage and healthy profitability.
Risks for the Ajanta Pharma Share Price
The absence of a disclosed trigger for today's fall is itself a risk, since investors cannot fully assess whether the move reflects a temporary reaction or a more durable concern until further information emerges. US FDA inspection and regulatory risk is a standing factor for Indian pharmaceutical exporters generally, including Ajanta's own facilities. Broader sector rotation out of pharma stocks, if that is contributing to today's move, would be a market-wide rather than company-specific risk, but would still affect near-term returns.
Download the Univest iOS App or Univest Android App to track the Ajanta Pharma share price and get alerts on company disclosures.
Conclusion
The Ajanta Pharma share price fell 2.82 percent to Rs 3,512, its steepest single-day decline in six months, with no company disclosure found to explain the move. A reasonable valuation in line with the pharma industry average and strong return on equity of 23.33 percent are supports, while the lack of a confirmed trigger and standing US regulatory risk are the concerns to watch. Investors deciding whether to buy Ajanta Pharma shares should watch the Rs 3,534.12 average as resistance, follow stop-loss levels and consult a SEBI-registered adviser.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the Ajanta Pharma share price today?
Ans. The Ajanta Pharma share price was Rs 3,512 at 10:12 AM on 1 October 2026, down 2.82 percent from Rs 3,620.80.
Why is the Ajanta Pharma share price falling today?
Ans. No specific company disclosure explaining the fall was found in the filings reviewed, so no confirmed cause can be assigned to today's decline.
Is this Ajanta Pharma's biggest fall in recent months?
Ans. Yes. Today's decline marks the stock's steepest single-day fall in six months.
Is the Ajanta Pharma share price expensive?
Ans. The P/E of 39.83 is close to the pharmaceutical industry average of 38.34, so the stock is roughly in line with sector peers.
What are the key technical levels for the Ajanta Pharma share price?
Ans. The key levels are SuperTrend resistance at Rs 3,740.42 and the 20-day average of Rs 3,534.12. The RSI is 49.2, neutral.
How far is Ajanta Pharma from its 52-week high?
Ans. The stock is about 7.5 percent below its 52-week high of Rs 3,796.
What is Ajanta Pharma's return on equity?
Ans. Return on equity is 23.33 percent, with a low debt to equity of 0.06, reflecting a financially strong business.
Should I buy Ajanta Pharma shares after this fall?
Ans. Without a confirmed reason for the decline, caution is warranted. Use a stop-loss, avoid overexposure and consult a SEBI-registered adviser.
Recent Articles

3B Blackbio Dx Ltd. (3BBLACKBIO): 3B Blackbio Dx Ltd 52 Week High Streak Holds For Second Straight Session
1 October 2026

Lemon Tree Hotels (LEMONTREE) Share Price rises 6.33% as LEMONTREE trades higher
1 October 2026

Maestros Electronics & Telecommunications Systems (METSL) Share Price Rises 8.46% Today
1 October 2026

Infinium Pharmachem Ltd. (INFINIUM) Share Price Rise Streak: Second Straight Session Gains 18.95%
1 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
3B Blackbio Dx Ltd. (3BBLACKBIO): 3B Blackbio Dx Ltd 52 Week High Streak Holds For Second Straight Session
Lemon Tree Hotels (LEMONTREE) Share Price rises 6.33% as LEMONTREE trades higher
Maestros Electronics & Telecommunications Systems (METSL) Share Price Rises 8.46% Today
Infinium Pharmachem Ltd. (INFINIUM) Share Price Rise Streak: Second Straight Session Gains 18.95%
Syrma SGS Technology Ltd. (SYRMA) 52 Week High Streak: Consecutive High Analysis
Popular this week
Vikram Solar Ltd. (VIKRAMSOLR): Vikram Solar Share Price Near 52-Week Low as Stock Trades at Rs 157.25

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





